01 November 2022
High Blood Cholesterol is amongst the top three non-communicable diseases (NCDs) , and has the highest prevalence compared to diabetes and high blood pressure.
Collaboration between Novartis Singapore and Singapore Heart Foundation will seed new initiatives to enhance education on cholesterol management and the potential risks leading to complications of heart attack and stroke.
The multi-year partnership, aimed at unblocking barriers to better heart health, supports Singapore’s Healthier SG strategy to place a sustained focus on preventive care in achieving overall healthier living.
Singapore, 1 November 2022 – Novartis Singapore (Novartis) and Singapore Heart Foundation (SHF) signed a Memorandum of Understanding (MoU) to collaborate on a 3-year campaign to raise awareness of high blood cholesterol and cholesterol management amongst the general public, patients and caregivers in Singapore. In support of the Healthier SG vision, the collaboration aims to amplify education around high blood cholesterol to be recognised as an important modifiable cardiovascular disease (CVD) risk factor and drive a concerted effort towards preventive care.
Under the MoU agreement – signed by Novartis Singapore Country President, Ms. Poh Hwee Tee and SHF Chief Executive Officer, Mr. Vernon Kang – Novartis and SHF will join efforts to make cholesterol management a priority in the healthcare ecosystem, raise awareness and urgency amongst Singaporeans towards the severity and complications of high blood cholesterol and cholesterol management. The signing ceremony, which marks the start of a multi-year strategic partnership, was witnessed by Ms. Ruth Kuguru, Executive Director Communications and Engagement, Novartis Asia Pacific, Middle East and Africa (APMA) and Dr. Bernard Kwok, SHF Board Member and Chairperson of SHF Corporate Partnership Committee.